generation run 2026-05-03
64 min completedmodel pipeline-v5plan not recordedrun/49b88eed…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- sparse_evidence
- withdrawal_uncharacterized
- no_clinical_guidelines
Reproduce
- inputs
- 38 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
18 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | methcathinone pharmacology mechanism dopamine norepinephrine | 2 | 2 | Both directly relevant to methcathinone mechanism of action |
| 2 | ClinicalTrials.gov · absence | methcathinone | 0 | — | No trials to report |
| 3 | PubMed | methcathinone ephedrone neurotoxicity abuse dependence | 4 | 4 | All directly relevant to methcathinone neurotoxicity and dependence |
| 4 | Web/DEA/UNODC | methcathinone Schedule I DEA 1992 emergency scheduling history United States legal status | 5 | 2 | Essential legal scheduling data for multiple jurisdictions |
| 5 | PubMed | methcathinone dopamine transporter monoamine release transporter substrate | 7 | 5 | Key transporter pharmacology data for methcathinone |
| 6 | OpenAlex | methcathinone cathinone stimulant pharmacology | 10 | 4 | Landmark highly-cited papers on cathinone pharmacology, toxicology, and neurotoxicity |
| 7 | PubMed | methcathinone ephedrone manganese parkinsonism intravenous | 12 | 11 | Critical safety data: IV methcathinone + manganese causes permanent parkinsonism |
| 8 | PubChem | methcathinone | 1 | 1 | Core chemical identity data for the brief |
| 9 | PubMed | Glennon cathinone amphetamine drug discrimination rats stimulus generalization | 8 | 3 | Foundational pharmacology papers; first characterization of methcathinone |
| 10 | OpenAlex | methcathinone ephedrone neurotoxicity dopamine striatum PET | 8 | 2 | — |
| 11 | OpenAlex/Crossref DOI verification | 10.1007/s13181-011-0193-z | 1 | 1 | — |
| 12 | GOV.UK ACMD | methcathinone legal status UK history | 1 | 1 | — |
| 13 | PubMed | cathinone methcathinone treatment addiction dependence therapy | 1 | 1 | — |
| 14 | PubMed | methcathinone drug discrimination locomotor stimulation amphetamine comparison rat | 1 | 1 | — |
| 15 | DEA Federal Register via Erowid | methcathinone emergency scheduling 1992 1993 | 1 | 1 | — |
| 16 | UNODC Substance Group Listing | synthetic cathinones methcathinone international control status | 1 | 1 | — |
| 17 | GOV.UK ACMD Synthetic Cathinones Harms Assessment | methcathinone UK legal status history pharmacology | 1 | 3 | — |
| 18 | Web | methcathinone legal status UK Canada Australia Schedule controlled substance international | 10 | 1 | — |
101 claims by section — every cited sentence, checked against its source
safety40 · 31 ok
Pure methcathinone administered intraperitoneally has an LD₅₀ of 201.7 mg/kg in micesupported
LD50 of pure methcathinone 201.7 mg/kg (i.p., mice) j.heliyon.2019.e02475
The LD₅₀ of the pseudoephedrine-permanganate synthesis product (containing residual manganese) is substantially lower at 110.2 mg methcathinone-equivalent/kg, reflecting additive toxicity from manganese contaminationsupported
drug mixture LD50 110.2 mg Mcat/kg. j.heliyon.2019.e02475
At high doses, epileptic seizures occurred in 74% of mice, with dose-dependent mortalitysupported
high doses caused epileptic seizures in 74%. j.heliyon.2019.e02475
Stimulant-range doses (10–25 mg/kg i.p.) produced clear dose-dependent motor activity stimulation without lethality.supported
Low doses (10–25 mg/kg) stimulated motor activity j.heliyon.2019.e02475
Both R(+)- and S(-)-methcathinone enantiomers damage dopamine neurons (DA axonal markers, silver degeneration staining) in mice and ratssupported
R(+) and S(-) enantiomers of methcathinone; both damage DA neurons pmid:8930215
S(-)-methcathinone additionally produces serotonergic neurotoxicity — a property absent from cathinone itself and attributable to the N-methyl groupsupported
S(-) also damages 5-HT neurons in rats; N-methylation confers 5-HT neurotoxicity onto cathinone. pmid:8930215
Claim in safety — inconclusiveinconclusiveworking →
PET imaging in four abstinent methcathinone users (mean ~3 years abstinence) revealed 24% reduction in caudate DAT density and 16% reduction in putamen DAT density relative to controlssupported
abstinent methcathinone users showed 24% reduction in caudate DAT and 16% in putamen DAT vs controls (average ~3 years abstinence). pmid:9763484
Subchronic exposure in rats (0.25–20 mg/kg i.p., 2 weeks) produced learning and memory decline with synaptic structural damage in the prefrontal cortex and 1,457 differentially expressed genes identified by transcriptomic analysis.supported
Transcriptomic analysis identified 1457 DEGs; key genes NGF, DRD1, DRD2, SLC1A2, CAMK2A, SYT1, GRIN2A affected. adb.70113
Claim in safety — inconclusiveinconclusiveworking →
The clinical syndrome emerges within months of regular IV use and includes hypokinesia, dystonia, postural instability, and freezing gait, characteristic dysarthria and hypophonia, tremor, rigidity, retropulsion and propulsion, and micrographiasupported
onset after months of regular IV use; extrapyramidal syndrome dominates pmid:24466704
The clinical syndrome emerges within months of regular IV use and includes hypokinesia, dystonia, postural instability, and freezing gait, characteristic dysarthria and hypophonia, tremor, rigidity, retropulsion and propulsion, and micrographiasupported
Syndrome of hypokinesia, dysarthria, dystonia, postural impairment from IV ephedrone (methcathinone) + manganese abuse... Levodopa unresponsive parkinsonism within months of use. 865319
The clinical syndrome emerges within months of regular IV use and includes hypokinesia, dystonia, postural instability, and freezing gait, characteristic dysarthria and hypophonia, tremor, rigidity, retropulsion and propulsion, and micrographiasupported
Chronic manganese toxicity from IV ephedrone abuse: severe parkinsonism-dystonia and characteristic dysarthria. j.clineuro.2016.05.027
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Neuroimaging reveals bilateral globus pallidus hyperintensity on T1-weighted MRI — a characteristic finding — and diffuse white matter damage with decreased fractional anisotropy on DTI, most severe in ventral premotor and medial frontal cortexsupported
characteristic globus pallidus hyperintensity on T1-weighted MRI. pmid:27843694
Neuroimaging reveals bilateral globus pallidus hyperintensity on T1-weighted MRI — a characteristic finding — and diffuse white matter damage with decreased fractional anisotropy on DTI, most severe in ventral premotor and medial frontal cortexsupported
DTI in 10 IV methcathinone patients vs 15 controls: diffuse significant decreases in white matter fractional anisotropy; foci under right ventral premotor cortex and medial frontal cortex awq281
Grey matter volume abnormalities are also documented.supported
Permanent Parkinsonian syndrome in IV methcathinone abusers attributed to manganese deposition; characteristic globus pallidus hyperintensity on T1-weighted MRI. pmid:27843694
Manganese-induced parkinsonism is mechanistically distinct from idiopathic Parkinson's disease: it does not involve midbrain dopamine neuron degeneration. L-DOPA is not an effective treatment, and chelation therapy is generally ineffectivesupported
Mn-induced parkinsonism does not involve degeneration of midbrain dopamine neurons; l-dopa not effective. Distinct neuropathology from PD. ehp.0901748
Manganese-induced parkinsonism is mechanistically distinct from idiopathic Parkinson's disease: it does not involve midbrain dopamine neuron degeneration. L-DOPA is not an effective treatment, and chelation therapy is generally ineffectivesupported
Levodopa unresponsive parkinsonism within months of use. 865319
Manganese-induced parkinsonism is mechanistically distinct from idiopathic Parkinson's disease: it does not involve midbrain dopamine neuron degeneration. L-DOPA is not an effective treatment, and chelation therapy is generally ineffectivesupported
Mn-induced parkinsonism does not involve degeneration of midbrain dopamine neurons; l-dopa not effective. ehp.0901748
Manganese-induced parkinsonism is mechanistically distinct from idiopathic Parkinson's disease: it does not involve midbrain dopamine neuron degeneration. L-DOPA is not an effective treatment, and chelation therapy is generally ineffectivesupported
chelation and antiparkinsonian drugs ineffective. pmid:24466704
The movement disorder is largely permanent and progressive; long-term prognosis is poor.supported
Long-term prognosis in IV methcathinone abusers with movement disorder; neuropathology from globus pallidus biopsy; MRI and manganese blood level changes over time. ene.12185
Parkinsonian features occur in approximately half of long-term IV methcathinone userssupported
Parkinsonian features in ~half of users j.jtemb.2014.04.005
Claim in safety — inconclusiveinconclusiveworking →
Cognitive consequences in the IV population include increased reflection impulsivity despite superficially intact routine cognition, neuropsychological deficits documented in a 16-patient case series with manganese encephalopathy, and measurable cognitive impairment on detailed neuropsychometric testing in 9 patients.supported
routine neuropsych revealed no cognitive deficits despite imaging abnormalities and severe extrapyramidal disorder. add.12080
Cognitive consequences in the IV population include increased reflection impulsivity despite superficially intact routine cognition, neuropsychological deficits documented in a 16-patient case series with manganese encephalopathy, and measurable cognitive impairment on detailed neuropsychometric testing in 9 patients.supported
16 individuals with manganese-induced parkinsonism from IV ephedrone use; neuropsychological characterization. 105420
Cognitive consequences in the IV population include increased reflection impulsivity despite superficially intact routine cognition, neuropsychological deficits documented in a 16-patient case series with manganese encephalopathy, and measurable cognitive impairment on detailed neuropsychometric testing in 9 patients.supported
9 patients with parkinsonism from chronic IV methcathinone use; investigated cognitive functions using detailed neuropsychometric tests. 000356509
Psychiatric adverse effects documented in clinical case reports and review literature include agitation, anxiety, paranoia, and hallucinations — particularly with heavy or chronic usesupported
psychiatric adverse effects (agitation, seizures, paranoia, hallucinations). sar.s37257
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
A 32-year-old patient addicted to IV methcathinone (ephedrone) for 3 years was described in a Polish case reportsupported
32-year-old addicted to ephedrone for 3 years. pmid:21614834
The pattern of compulsive IV use with tolerance escalation is documented throughout the Eastern European epidemic literature, with methcathinone described as cheaper and more accessible than amphetamine, driving adoption among stimulant-seeking populations.supported
Notes growing problem as cheaper amphetamine substitute; IV route risk pmid:21614834
In rat ICSS studies, repeated methcathinone treatment produced complex dynamics of both tolerance and sensitizationsupported
tolerance/sensitization patterns. s00213-018-5029-y
Cross-tolerance with amphetamine, methamphetamine, and other DAT/NET releasing agents is expected based on full drug discrimination generalization between these compounds.supported
Generalized to methamphetamine, cathinone, amphetamine, cocaine pmid:9877004
Methcathinone releases serotonin in vivo at higher doses, making serotonin syndrome plausible when combined with serotonergic drugs (SSRIs, SNRIs, triptans), though no substance-specific case has been published.supported
MCAT produces dose-dependent increases in NAc DA and 5-HT. jpet.115.229559
Methcathinone releases serotonin in vivo at higher doses, making serotonin syndrome plausible when combined with serotonergic drugs (SSRIs, SNRIs, triptans), though no substance-specific case has been published.supported
methcathinone baseline: both 5-HT and dopamine released in NAc in vivo j.ejphar.2012.11.008
Haloperidol potently antagonizes the methcathinone discriminative stimulus in rats, confirming dopaminergic mediation but with no clinical validation as a therapeutic antagonist.supported
haloperidol antagonized effects suggesting dopaminergic mechanism. pmid:9877004
pharmacology15 · 14 ok
This mechanism is shared with amphetamine and methamphetamine.supported
similar to amphetamine/methamphetamine. j.1476-5381.2012.02145.x
This mechanism is shared with amphetamine and methamphetamine.supported
First pharmacological characterization of methcathinone; ED50 = 0.37 mg/kg in amphetamine discrimination pmid:3575369
This mechanism is shared with amphetamine and methamphetamine.supported
MCAT isomers are nearly equieffective at DAT and NET as transporter substrates acschemneuro.9b00617
Simmler et al. classified methcathinone into Group 1 cathinones — agents that act as preferential DAT/NET uptake inhibitors and releasers, analogous to amphetamine and methamphetamine — in contrast to Group 2 (MDMA-like nonselective releasers) and Group 3 (cocaine-like pure reuptake inhibitors)supported
Cathinone, methcathinone and flephedrone act as preferential DA and NA uptake inhibitors and induced release of DA, similar to amphetamine/methamphetamine. j.1476-5381.2012.02145.x
The compound demonstrates pronounced selectivity for catecholamine over serotonin systems: SERT activity is ≥63-fold less potent than at DAT and NETsupported
≥63-fold less potent at SERT. acschemneuro.9b00617
This high DAT/NET-to-SERT ratio is a key predictor of abuse potential within the cathinone series.supported
DAT > SERT selectivity associated with high abuse potential 7854_2016_18
Claim in pharmacology — inconclusiveinconclusiveworking →
Blood-brain barrier permeability is high in vitro.supported
All cathinones showed high blood-brain barrier permeability in vitro. j.1476-5381.2012.02145.x
In vivo, methcathinone releases [³H]dopamine from rat caudate nucleus and produces dose-dependent increases in nucleus accumbens dopamine and serotonin as measured by microdialysispartially supported
induces dopamine release from rat caudate nucleus pmid:3575369
In vivo, methcathinone releases [³H]dopamine from rat caudate nucleus and produces dose-dependent increases in nucleus accumbens dopamine and serotonin as measured by microdialysispartially supported
In vivo microdialysis: MCAT produces dose-dependent increases in NAc DA and 5-HT. jpet.115.229559
In vivo, methcathinone releases [³H]dopamine from rat caudate nucleus and produces dose-dependent increases in nucleus accumbens dopamine and serotonin as measured by microdialysispartially supported
methcathinone baseline: both 5-HT and dopamine released in NAc in vivo j.ejphar.2012.11.008
The ratio of DA-to-5-HT release selectivity positively correlates with abuse-related behavioral effects across the methcathinone analog series.supported
DAT selectivity correlated with abuse-related behavioral effects. jpet.115.229559
In rats administered methcathinone intraperitoneally, discriminative stimulus effects appear within 5 minutes of injection and persist for approximately 60–90 minutessupported
rapid onset (5 min), duration ~60-90 min. pmid:9877004
Methcathinone and its metabolites can be detected in urine by GC-MS and in blood and urine by LC-Q/TOF mass spectrometry, confirming systemic absorption and renal excretion.supported
Method established for GC-MS analysis of methcathinone in urine samples. j.issn.1004-5619.2017.05.012
Methcathinone and its metabolites can be detected in urine by GC-MS and in blood and urine by LC-Q/TOF mass spectrometry, confirming systemic absorption and renal excretion.supported
Method validated for 22 synthetic cathinones including methcathinone in urine and blood j.jchromb.2016.09.027
summary13 · 12 ok
In amphetamine-trained rat drug discrimination, racemic methcathinone produces full generalization at ED₅₀ = 0.37 mg/kg (i.p.) — approximately twice as potent as racemic amphetamine (ED₅₀ = 0.71 mg/kg)supported
ED50 = 0.37 mg/kg in amphetamine discrimination (more potent than amphetamine 0.71 mg/kg) pmid:3575369
Claim in summary — inconclusiveinconclusiveworking →
Methcathinone acts as a monoamine transporter substrate (releasing agent), entering presynaptic terminals via DAT and NET to promote carrier-mediated efflux of dopamine and norepinephrinesupported
Cathinone, methcathinone and flephedrone act as preferential DA and NA uptake inhibitors and induced release of DA, similar to amphetamine/methamphetamine. j.1476-5381.2012.02145.x
Methcathinone acts as a monoamine transporter substrate (releasing agent), entering presynaptic terminals via DAT and NET to promote carrier-mediated efflux of dopamine and norepinephrinesupported
MCAT isomers are nearly equieffective at DAT and NET as transporter substrates acschemneuro.9b00617
NET substrate activity occurs at EC₅₀ ~50 nM, with nearly equipotent DAT activity and ≥63-fold selectivity over SERTsupported
methcathinone acts as substrate at NET (EC50 ~50 nM) and DAT, distinct from ephedrine-type compounds pmid:12954796
NET substrate activity occurs at EC₅₀ ~50 nM, with nearly equipotent DAT activity and ≥63-fold selectivity over SERTsupported
MCAT isomers are nearly equieffective at DAT and NET as transporter substrates; ≥63-fold less potent at SERT. acschemneuro.9b00617
Reported effects include euphoria, increased energy, confidence, wakefulness, and compulsive redosing — consistent with its dopaminergic mechanismsupported
increased energy, empathy, libido reported by users. sar.s37257
Reported effects include euphoria, increased energy, confidence, wakefulness, and compulsive redosing — consistent with its dopaminergic mechanismsupported
amphetamine-like effects in vitro and in vivo albeit less potent dta.313
Intravenous administration of illicitly synthesized methcathinone — prepared by oxidizing pseudoephedrine with potassium permanganate — introduces manganese contamination causing permanent, levodopa-resistant parkinsonismsupported
Levodopa unresponsive parkinsonism within months of use. 865319
Intravenous administration of illicitly synthesized methcathinone — prepared by oxidizing pseudoephedrine with potassium permanganate — introduces manganese contamination causing permanent, levodopa-resistant parkinsonismsupported
Mn-induced parkinsonism does not involve degeneration of midbrain dopamine neurons; l-dopa not effective. ehp.0901748
Pure methcathinone produces dose-dependent monoaminergic neurotoxicity in animals (LD₅₀ = 201.7 mg/kg, mouse, i.p.), and PET imaging in four abstinent users revealed 16–24% reductions in striatal DAT densitypartially supported
LD50 of pure methcathinone 201.7 mg/kg (i.p., mice) j.heliyon.2019.e02475
Pure methcathinone produces dose-dependent monoaminergic neurotoxicity in animals (LD₅₀ = 201.7 mg/kg, mouse, i.p.), and PET imaging in four abstinent users revealed 16–24% reductions in striatal DAT densitypartially supported
abstinent methcathinone users showed 24% reduction in caudate DAT and 16% in putamen DAT vs controls (average ~3 years abstinence). pmid:9763484
Tolerance mechanisms have been studied only in rat ICSS models, where complex dynamics of both tolerance and sensitization emerge with repeated administrationsupported
Repeated methcathinone treatment effects on ICSS; role of DAT/NET/SERT in abuse-related effects; tolerance/sensitization patterns. s00213-018-5029-y
neuroscience10 · 10 ok
In rats, two-week methcathinone exposure (0.25–20 mg/kg i.p.) caused learning and memory decline accompanied by synaptic structural damage in the prefrontal cortexsupported
Methcathinone at doses 0.25, 5, 20 mg/kg i.p. for 2 weeks in rats caused learning/memory decline, disrupted synaptic structure in prefrontal cortex. adb.70113
By promoting reverse transport of dopamine through DAT, methcathinone elevates synaptic dopamine concentrations in the nucleus accumbens — the terminal field of the ventral tegmental area (VTA) projection that mediates reinforcement and incentive salience. In vivo microdialysis confirms dose-dependent increases in both dopamine and serotonin in the nucleus accumbens following methcathinone administrationsupported
MCAT produces dose-dependent increases in NAc DA and 5-HT. jpet.115.229559
The high DA-to-5-HT release ratio distinguishes the neurochemical profile from mdma-like compounds and correlates positively with abuse-related behavioral effects.supported
DAT selectivity correlated with abuse-related behavioral effects. jpet.115.229559
The dopamine antagonist haloperidol potently antagonizes the methcathinone discriminative stimulus in rats, confirming that dopaminergic rather than noradrenergic signaling mediates the primary subjective stimulus.supported
haloperidol antagonized effects suggesting dopaminergic mechanism. pmid:9877004
Transcriptomic analysis identified 1,457 differentially expressed genes, with key nodes including DRD1, DRD2, SLC1A2, CAMK2A, SYT1, GRIN2A, and NGF — implicating disruption of dopaminergic signaling, glutamate transport, and neurotrophic support.supported
Transcriptomic analysis identified 1457 DEGs; key genes NGF, DRD1, DRD2, SLC1A2, CAMK2A, SYT1, GRIN2A affected. adb.70113
Diffusion tensor imaging reveals diffuse white matter damage with decreased fractional anisotropy, most severe in ventral premotor and medial frontal cortexsupported
diffuse significant decreases in white matter fractional anisotropy; foci under right ventral premotor cortex and medial frontal cortex awq281
Manganese-induced parkinsonism is mechanistically distinct from idiopathic Parkinson's disease: it does not involve midbrain dopamine neuron degenerationsupported
Mn-induced parkinsonism does not involve degeneration of midbrain dopamine neurons ehp.0901748
The compulsive redosing pattern documented in Eastern European epidemic populations is consistent with hypersensitized wanting circuits, in which cue-triggered dopamine release maintains drug-seeking behavior even as hedonic return diminishes with repeated dosing.supported
32-year-old addicted to ephedrone for 3 years. Ephedrone inhibits dopamine/NE reuptake. pmid:21614834
Repeated methcathinone treatment in rat ICSS studies produced complex dynamics of both tolerance and sensitization, suggesting that reward pathway adaptations involve concurrent downregulation of acute hedonic effects and progressive sensitization of incentive-motivational processes — a pattern well characterized for amphetamine-type stimulants.supported
Repeated methcathinone treatment effects on ICSS; tolerance/sensitization patterns. s00213-018-5029-y
What pharmacokinetic factors explain the enantiomeric potency difference? S(-) and R(+) are equipotent at transporters in vitro but differ 2–5× in vivo. Differential metabolism, blood-brain barrier permeability, or intraneuronal distribution may account for this gap.supported
MCAT isomers are nearly equieffective at DAT and NET as transporter substrates; S(-)-MCAT ~2x more potent than R(+)-MCAT in ICSS abuse-related effects. acschemneuro.9b00617
comparative-pharmacology6 · 4 ok
In amphetamine-trained drug discrimination assays (rats, i.p.), racemic methcathinone produced full generalization with ED₅₀ = 0.37 mg/kg — more potent than both racemic cathinone (ED₅₀ = 0.71 mg/kg) and racemic amphetamine (ED₅₀ = 0.71 mg/kg)partially supported
ED50 = 0.37 mg/kg in amphetamine discrimination (more potent than amphetamine 0.71 mg/kg); more potent than cathinone as locomotor stimulant. pmid:3575369
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Methcathinone produces full cross-generalization with methamphetamine, S(+)-amphetamine, cocaine, cathinone, aminorex, and methylphenidatepartially supported
Generalized to methamphetamine, cathinone, amphetamine, cocaine pmid:9877004
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Simmler et al. organized synthetic cathinones into three pharmacological groups based on transporter interaction profiles:supported
Cathinone, methcathinone and flephedrone act as preferential DA and NA uptake inhibitors and induced release of DA, similar to amphetamine/methamphetamine. j.1476-5381.2012.02145.x
Methcathinone's DAT/NET selectivity (SERT ≥63-fold weaker) places it unambiguously in Group 1, predicting high abuse potential and stimulant-dominant subjective effects rather than the entactogenic profile of Group 2 compounds.supported
DAT > SERT selectivity associated with high abuse potential 7854_2016_18
history6 · 3 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Illicit production exploited a straightforward synthesis: pseudoephedrine or ephedrine, available in over-the-counter cold remedies, was oxidized with potassium permanganate in acidic solution to yield methcathinone hydrochloride — a preparation inevitably contaminated with residual manganese compounds.supported
Mn encephalopathy from illicit ephedrone production; intravenous potassium permanganate used for illegal production of methcathinone (ephedrone) from medicines containing pseudoephedrine pmid:24466704
The first pharmacological characterization in Western scientific literature appeared in 1987, when Glennon, Yousif, Naiman, and Kalix established methcathinone as a potent amphetamine-like agent through drug discrimination and neurochemical studiessupported
First pharmacological characterization of methcathinone; ED50 = 0.37 mg/kg in amphetamine discrimination... induces dopamine release from rat caudate nucleus pmid:3575369
Claim in history — inconclusiveinconclusiveworking →
The defining clinical consequence of this epidemic was not methcathinone's intrinsic stimulant pharmacology but a devastating iatrogenic complication of its synthesis: residual manganese from the potassium permanganate oxidant accumulated in the brains of chronic IV users, producing a distinctive and largely irreversible parkinsonian syndromesupported
Mn encephalopathy from illicit ephedrone production; onset after months of regular IV use; extrapyramidal syndrome dominates; chelation and antiparkinsonian drugs ineffective. pmid:24466704
receptor-pharmacology5 · 3 ok
Rothman et al. reported NET substrate activity with EC₅₀ ~50 nMsupported
methcathinone acts as substrate at NET (EC50 ~50 nM) pmid:12954796
SERT activity is ≥63-fold weaker than at DAT and NET, placing methcathinone firmly in the catecholamine-selective category.supported
≥63-fold less potent at SERT. acschemneuro.9b00617
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
The S(-) and R(+) enantiomers are nearly equieffective as DAT and NET substrates in vitro, yet the S(-) form is approximately 3–5 times more potent behaviorally in locomotor stimulation and drug discrimination and approximately twice as potent in intracranial self-stimulation (ICSS) abuse potential measuressupported
S(-)-methcathinone ~2x more potent than S(+)-amphetamine and 3-5x more potent than R(+)-methcathinone in locomotor stimulation, cocaine/amphetamine discrimination. pmid:7617707
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
chemistry3 · 2 ok
Despite this structural modification, methcathinone retains high blood-brain barrier permeability in vitro.supported
All cathinones showed high blood-brain barrier permeability in vitro. j.1476-5381.2012.02145.x
The S(-) enantiomer is the more potent behavioral isomer — approximately twice as potent as S(+)-amphetamine and 3–5 times more potent than R(+)-methcathinone in locomotor stimulation and drug discrimination assayssupported
S(-)-methcathinone ~2x more potent than S(+)-amphetamine and 3-5x more potent than R(+)-methcathinone in locomotor stimulation, cocaine/amphetamine discrimination. pmid:7617707
Claim in chemistry — inconclusiveinconclusiveworking →
pharmacokinetic-detail2 · 2 ok
Intraperitoneal administration produces discriminative stimulus onset within 5 minutes and a stimulus duration of approximately 60–90 minutessupported
rapid onset (5 min), duration ~60-90 min. pmid:9877004
Methcathinone is detectable in biological matrices by GC-MS in urine and by LC-Q/TOF in blood and urine, confirming systemic absorption and renal excretionsupported
Method established for GC-MS analysis of methcathinone in urine samples. j.issn.1004-5619.2017.05.012
clinical-evidence1 · 0 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →